<DOC>
	<DOCNO>NCT02674893</DOCNO>
	<brief_summary>This open-label comparative study three parallel group . It expect 90 patient and/or healthy volunteer participate biomedical research . Distribution group - 30 patient type 2 diabetes indication treatment GLP1 analogue ( group 1 ) - 30 patient type 2 diabetes ( control diabetic subject ) treat Incretins ( group 2 ) - 30 healthy subject ( non-diabetics ) ( group 3 ) This study investigate modification eat behaviour induce Liraglutide patient start treatment Victoza® certain aspect , like ( hedonic characteristic food ) , want ( desire eat give food ) salivation response presentation food take measurement D0 ( initiation treatment Liraglutide group concern ) 15 day ( except control ) , 3 month 9 month ( control ) .</brief_summary>
	<brief_title>Effect Victoza Dietary Preferences Habit Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>DIABETIC PATIENTS TREATED WITH LIRAGLUTIDE person provide write informed consent age &gt; 18 year type 2 diabetes HbA1C &gt; 7 % overweight ( BMI &gt; 27 ) normal renal function ( creatinine clearance &gt; 50ml/min ) patient treat Liraglutide ( patient type 2 diabetes HbA1C &gt; 7.5 % overweight obesity , whose current treatment insufficient control diabetes ) . CONTROL DIABETIC PATIENTS person provide write informed consent age &gt; 18 year type 2 diabetes HbA1C &gt; 7 % overweight ( BMI &gt; 27 ) patient treatment Liraglutide indicate normal renal function ( creatinine clearance &gt; 50ml/min ) HEALTHY SUBJECTS person provide write informed consent age &gt; 18 year DIABETIC PATIENTS TREATED WITH LIRAGLUTIDE type 1 diabetes decompensated congestive heart failure acute chronic infection , progressive cancer , liver cirrhosis ongoing treatment antibiotic smoke chronic alcohol abuse ( &gt; 4 glass day ) aversion product eat smelled poor understand cognitive task request treatment interfere olfactogustatory performance , psychotropic , antiemetic antiulcer drug person without national health insurance cover person guardianship hypersensitivity Liraglutide pregnancy , breastfeed history acute chronic pancreatitis calcitonin level selection ≥ 50 ng/L liver disease , define level alanine aminotransferase ( ALAT ) ≥ 2.5 time upper limit normal ( ULN ) reference value CONTROL DIABETIC PATIENTS type 1 diabetes , decompensated congestive heart failure , acute chronic infection , progressive cancer , liver cirrhosis , ongoing treatment antibiotic , smoke chronic alcohol abuse ( &gt; 4 glass day ) , aversion product eaten smell , poor understand cognitive task request , treatment interfere olfactogustatory performance , psychotropic , antiemetic antiulcer drug . person without national health insurance cover person guardianship HEALTHY SUBJECTS diabetes ( type I II ) sensory disorder decompensated congestive heart failure , acute chronic infection , progressive cancer , liver cirrhosis , ongoing treatment antibiotic , smoke chronic alcohol abuse ( &gt; 4 glass day ) , aversion product eaten smell , poor understand cognitive task request , treatment interfere olfactogustatory performance ( psychotropic , antiemetic , antiulcer drug ) person without national health insurance cover person guardianship contraindication MRI , notably , limit : pace maker , implantable cardiac defibrillator , neurostimulators , cochlear implant , certain implant automated injection system ( insulin pump ) , vascular intracerebral ferromagnetic clip , certain system regulate intravascular temperature , myopia require patient wear spectacle , history stroke transient ischemic attack ( TIA ) , metallic foreign body , particular intraocular situate near highrisk zone ( nervous system , vascular system ) , claustrophobia… .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>BMI &gt; 27</keyword>
	<keyword>Treatment Liraglutide</keyword>
</DOC>